Global Inflammatory Bowel Disease Treatment Market Set to Soar with Predicted 5.84% CAGR by 2034
January 29, 2024 05:04 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Inflammatory Bowel Disease Treatment Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. ...
Acute Pancreatitis Global Market Report 2024: Market to Surge to $7.41 Billion by 2028, Driven by Technological Advances and Growing Health Concerns - Long-term Forecast to 2033
January 25, 2024 09:14 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Acute Pancreatitis Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The latest acute pancreatitis market...
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
January 24, 2024 02:30 ET
|
Abivax
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 PARIS,...
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
January 09, 2024 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD),...
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
January 08, 2024 08:00 ET
|
Biora Therapeutics, Inc.
SAD/MAD study to evaluate safety and PK/PD of BT-600 drug-device combination, including concentrations in colon tissue
Global Stoma/Ostomy Care Market Report, 2022-2023 and 2024-2030 - Product Innovations and Advancements to Spur Market Expansion
January 08, 2024 07:33 ET
|
Research and Markets
Dublin, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The "Stoma/Ostomy Care - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Stoma/Ostomy Care Products...
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
December 27, 2023 06:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
December 19, 2023 08:00 ET
|
Biora Therapeutics, Inc.
Biora's latest patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract.
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 06, 2023 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and...
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
November 30, 2023 16:48 ET
|
Biora Therapeutics, Inc.
BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon